FeRx targets MCT (Magnetic Targeted Carrier) method at GI (gastrointestinal) diseases:
This article was originally published in Clinica
Preclinical results have suggested that FeRx' magnetic field-based drug delivery technique is a feasible method for delivering compounds to the gastrointestinal (GI) tract, the San Diego, California firm has reported. The Magnetic Targeted Carrier (MTC) technique may help treat GI diseases, such as inflammatory bowl disease and cancerous tumours of the oesophagus, stomach and colon, via an intra-luminal route of administration. FeRx has previously demonstrated delivery of MTCs via intra-arterial and intra-vesical routes of administration, possibly leading to the treatment of a variety of solid tumours, including those of the liver and bladder (see Clinica No 1004, p 24).
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.